Encision Reports Fiscal Year 2007 Results
15 Maio 2007 - 9:00AM
PR Newswire (US)
BOULDER, Colo., May 15 /PRNewswire-FirstCall/ -- Encision Inc.
(AMEX:ECI), a medical device company owning patented surgical
technology that is emerging as a standard of care in
minimally-invasive surgery, reported its financial results for its
fiscal year ended March 31, 2007. Revenue for the fiscal year ended
March 31, 2007 was $11 million, representing a 21% increase over
revenue of $9.1 million for the prior fiscal year. The Company
recorded a net loss of $90 thousand or $.01 per share for the
fiscal year 2007 compared to a net loss of $338 thousand or $.05
per share for the fiscal year 2006. Net loss for the fiscal year
2007 includes stock-based compensation expense of $182 thousand, or
$.03 per share, due to the implementation of SFAS 123( R ).
Financial results prior to fiscal year 2007 did not include
stock-based compensation expense. Net loss for the fiscal year 2007
also includes a one-time expense of $73 thousand, or $.01 per
share, relating to the costs of obtaining equity capital financing,
a project that was subsequently abandoned after the Company
obtained a $2 million credit facility from SVB Silicon Valley Bank.
Gross profit margin for the fiscal year 2007 was 63% as compared to
61% for the fiscal year 2006. Revenue for the fourth fiscal quarter
ended March 31, 2007 was $2.8 million, representing a 16% increase
over revenue of $2.4 million for the prior fiscal year's fourth
quarter. The Company recorded a net loss of $177 thousand or $.03
per share for the fourth quarter of fiscal year 2007 compared to a
net loss of $41 thousand or $.01 per share for the fourth quarter
of fiscal year 2006. Net loss for the fourth quarter of fiscal year
2007 includes stock-based compensation expense of $44 thousand, or
$.01 per share, due to the implementation of SFAS 123( R ).
Financial results prior to fiscal year 2007 did not include
stock-based compensation expense. The increased loss in this fiscal
year's fourth quarter as compared to the prior fiscal year's fourth
quarter was primarily a result of hiring additional engineers and
direct salespeople. Gross profit margins were 63% for the fourth
quarters of both fiscal year 2007 and 2006. Gross profit margin for
the fourth quarter of fiscal year 2006 was positively impacted by a
reduction of warranty expense of $62 thousand. Without the warranty
expense reduction, gross profit margin would have been
approximately 61%. "I am pleased to report that we had another
fiscal year of accelerating revenue growth," said Jack Serino,
President and CEO of Encision Inc. "Starting in the third quarter
and continuing through the fourth quarter of fiscal year 2007, we
began hiring for additional revenue growth initiatives. These
revenue growth initiatives include both the ability to offer a
disposable instrument option for each major reusable product and an
increase in the number of direct sales territories." Encision Inc.
designs, develops, manufactures and markets innovative surgical
devices that allow surgeons to optimize technique and patient
safety during a broad range of surgical procedures. Based in
Boulder, Colorado, the Company pioneered the development of
patented AEM(R) Laparoscopic Instruments to improve electrosurgery
and reduce the chance for patient injury in minimally invasive
surgery. In accordance with the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, the Company notes
that statements in this press release and elsewhere that look
forward in time, which include everything other than historical
information, involve risks and uncertainties that may cause actual
results to differ materially from those indicated by the
forward-looking statements. Factors that could cause the Company's
actual results to differ materially include, among others, its
ability to increase revenues through the Company's distribution
channels, insufficient quantity of new account conversions,
insufficient cash to fund operations, scale up production to meet
delivery obligations, delay in developing new products and
receiving FDA approval for such new products and other factors
discussed in the Company's filings with the Securities and Exchange
Commission. CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600,
ENCISION INC. Condensed Statements of Operations (Amounts in
thousands, except per share information) (Unaudited) (Audited)
Three Months Ended Fiscal Years Ended March 31, March 31, March 31,
March 31, 2007 2006 2007 2006 Revenue $2,817 $2,419 $11,010 $9,127
Cost of revenue 1,050 886 4,106 3,568 Gross profit 1,767 1,533
6,904 5,559 Operating expenses 1,947 1,581 7,035 5,913 Operating
loss (180) (48) (131) (354) Other income 3 7 41 16 Net loss $(177)
$(41) $(90) $(338) Basis/diluted net loss per share $(0.03) $(0.01)
$(0.01) $(0.05) ENCISION INC. Condensed Balance Sheets (Audited)
(Amounts in thousands) March 31, March 31, 2007 2006 Cash and cash
equivalents $436 $902 Current assets 3,637 3,325 Total assets 4,388
3,817 Current liabilities 1,464 1,085 Shareholders' equity 2,923
2,732 Total liabilities and shareholders' equity $4,388 $3,817
DATASOURCE: Encision Inc. CONTACT: Marcia McHaffie of Encision
Inc., +1-303-444-2600, Web site: http://www.encision.com/
Copyright
Encision (AMEX:ECI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Encision (AMEX:ECI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024